Wall Street Zen Downgrades Tilray Brands to Sell Amid Analyst Reviews

Tilray Brands, Inc. (NASDAQ: TLRY) has been downgraded from a “hold” rating to a “sell” rating by analysts at Wall Street Zen, as indicated in a report released on January 20, 2024. This assessment comes amid a series of recent evaluations from various financial institutions regarding the cannabis company’s stock performance.

Analysts from Roth MKM adjusted their price target for Tilray Brands, reducing it from **$20.00** to **$10.00** while maintaining a “neutral” rating. In contrast, Zacks Research upgraded the company from a “strong sell” to a “hold” rating. Canaccord Genuity Group also initiated coverage on Tilray Brands, issuing a “hold” rating in a report dated January 27, 2024. Weiss Ratings reaffirmed a “sell (d-)” rating for the stock, while ATB Cormark Capital Markets raised its rating from “strong sell” to “hold” on December 10, 2023.

The overall sentiment among analysts reflects a cautious approach, with one investment analyst giving a “buy” rating, six maintaining a “hold” rating, and one assigning a “sell” rating to the company. According to MarketBeat, the stock currently has an average rating of “hold” and an average target price of **$13.33**.

Current Stock Performance and Financial Overview

As of the market opening on January 19, 2024, shares of Tilray Brands traded at **$7.51**. The company has a market capitalization of **$874.99 million**, with a price-to-earnings ratio of **-0.34** and a beta of **2.02**. Over the past year, the stock has experienced significant volatility, reaching a low of **$3.51** and a high of **$23.20**. Its 50-day simple moving average stands at **$9.13**, while the two-hundred day average is **$10.99**. The company’s financial ratios indicate a debt-to-equity ratio of **0.19**, a current ratio of **2.81**, and a quick ratio of **1.72**.

In its most recent earnings report, released on January 8, 2024, Tilray Brands reported earnings per share of **($0.41)**, falling short of analysts’ expectations of **($0.14)** by **$0.27**. The company recorded revenues of **$217.51 million** for the quarter, which exceeded forecasts of **$211.15 million**. In the same period last year, Tilray reported earnings per share of **($0.03)**. Analysts predict that the company will post earnings of **-0.20** per share for the current fiscal year.

Institutional Investor Activity

Recent trading activity indicates a shift in institutional investment around Tilray Brands. Tidal Investments LLC increased its stake in the company by **15.0%** during the second quarter, acquiring **28,971,835** shares valued at approximately **$12 million**. Millennium Management LLC expanded its holdings by an impressive **281.0%** in the third quarter, now owning **4,942,319** shares worth about **$8.55 million**. Other notable investments include MIRAE ASSET GLOBAL ETFs HOLDINGS Ltd., which purchased a new position valued around **$5.81 million**, and Ausdal Financial Partners Inc., acquiring shares worth **$939,000**. Currently, approximately **9.35%** of Tilray Brands’ stock is owned by hedge funds and institutional investors.

Tilray Brands, Inc. is recognized as a global leader in the cannabis-lifestyle and consumer packaged goods sector. The company focuses on cultivating, producing, distributing, and selling cannabis and cannabinoid-based products. With a diverse portfolio that includes medical cannabis, adult-use recreational products, and wellness offerings, Tilray aims to meet various consumer needs through its advanced cultivation facilities and rigorous quality control systems.

The recent downgrades and mixed ratings from financial analysts highlight the challenges facing Tilray Brands as it navigates a fluctuating market and strives for profitability. With shifting investor sentiments and varying analyst perspectives, the company’s future performance will be closely monitored in the coming months.